LakeShore Biopharma (LSB) Stock Statistics & Valuation Metrics

LakeShore Biopharma has a market cap or net worth of $21.37M. The enterprise value is $323.18M.

LakeShore Biopharma has 41,212,692 shares outstanding. The number of shares has decreased by -2.65% in one year.

LakeShore Biopharma’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -41.04%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, LakeShore Biopharma had revenue of 573.42M and earned -433.46M in profits. Earnings per share was -4.05.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

LakeShore Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

LakeShore Biopharma upcoming earnings date is Aug 19, 2025, Before Open (Not Confirmed).

LakeShore Biopharma as a current ratio of 1.13, with Debt / Equity ratio of 72.53%

In the past 12 months, LakeShore Biopharma has paid -21.73M in taxes.

LakeShore Biopharma EV to EBITDA ratio is -15.69, with an EV/FCF ratio of -17.03.

LakeShore Biopharma has $246.35M in cash and marketable securities with ¥424.46M in debt, giving a net cash position of $178.11M billion.

Gross margin is 55.29%, with operating margin of -77.75%, and net profit margin of -75.59%.

The average price target for LakeShore Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―